Detailed Information
Cited 15 time in 
Cited 17 time in 
Cited 17 time in
Metadata Downloads
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Reportopen access
- Authors
- Song, Haa-Na; Kang, Min Gyu; Park, Jeong Rang; Hwang, Jin-Yong; Kang, Jung Hun; Lee, Won Seop; Lee, Gyeong-Won
- Issue Date
- Oct-2018
- Publisher
- KOREAN CANCER ASSOCIATION
- Keywords
- Sarcoma; Immunotherapy; Pembrolizumab
- Citation
- CANCER RESEARCH AND TREATMENT, v.50, no.4, pp 1458 - 1461
- Pages
- 4
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- CANCER RESEARCH AND TREATMENT
- Volume
- 50
- Number
- 4
- Start Page
- 1458
- End Page
- 1461
- ISSN
- 1598-2998
2005-9256
- Abstract
- Myxofibrosarcoma is a rare tumor, refractory to cytotoxic chemotherapy and radiotherapy. Pembrolizumab is an innovative immunotherapy drug consisting of programmed death receptor ligand 1 antibody proven to be useful for numerous types of cancer cells. A patient had been diagnosed with metastatic myxofibrosarcoma, refractory to radiotherapy and conventional cytotoxic chemotherapy. The patient achieved a partial response during palliative chemotherapy with pembrolizumab for 14 cycles. To the best of our knowledge, this is the first case report demonstrating the efficacy of pembrolizumab for refractory myxofibrosarcoma.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.